NeoGenomics, Inc. (NEO) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $8.39: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 5.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.33; Below-average business quality; Below long-term trend.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical... Read more
Sell if holding. Engine safety override at $8.39: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 5.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.33; Below-average business quality; Below long-term trend. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.9/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 70d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — NeoGenomics, Inc.
Latest news
- Earnings Scheduled For May 12, 2026 — benzinga May 12, 2026 neutral
- Benchmark Upgrades NeoGenomics to Buy, Announces $11 Price Target — benzinga Apr 29, 2026 positive
- TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $14 — benzinga Apr 29, 2026 positive
- Leerink Partners Upgrades NeoGenomics to Outperform, Raises Price Target to $25 — benzinga Apr 29, 2026 positive
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session — benzinga Apr 29, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Unprofitable operations — net margin -13.3%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.39: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 5.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.33; Below-average business quality; Below long-term trend. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $7.80. Score 5.9/10, moderate confidence.
Take-profit target: $13.10 (+56.1% upside). Prior stop was $7.80. Stop-loss: $7.80.
Quality below floor (3.6 < 4.0).
NeoGenomics, Inc. trades at a P/E of N/A (forward 23.0). TrendMatrix value score: 8.6/10. Verdict: Sell.
17 analysts cover NEO with a consensus score of 3.8/5. Average price target: $15.
What does NeoGenomics, Inc. do?NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United...
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.